Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several challenges: revenue and gross profit declines, competitive pressures, and margin compression. Despite share repurchases, the financial performance is weak with declining revenue and pressured margins. The Q&A highlights concerns about margin pressures and unclear future guidance, indicating potential uncertainties. The market strategy and financial health ratings are negatively impacted by these factors, leading to an overall negative sentiment.
Consolidated Revenue $315 million, down 29% year-over-year, driven primarily by expected declines in Travel, Nurse and Allied.
Gross Profit $64 million, with a gross margin of 20.4%, down 160 basis points year-over-year due to bill pay spread compression in the travel business.
Selling, General and Administrative Expense $54 million, down 22% year-over-year, primarily due to lower salary and benefit costs from headcount reductions.
Adjusted EBITDA $10 million, representing a margin of 3.3%, reflecting lower revenue and gross margin pressure.
Adjusted Earnings Per Share $0.12, at the high end of the guidance range, primarily due to lower stock compensation and discrete tax benefits.
Nurse and Allied Revenue $265 million, down 33% year-over-year, with Travel down 41% year-over-year.
Home Care Staffing Revenue Up 13% year-over-year, driven by recent PACE program wins.
Physician Staffing Revenue $50 million, up 10% year-over-year, with billable days up 6% year-over-year.
Cash from Operations $7.5 million for the quarter, with $96 million for the 9 months.
Cash Position $64 million in cash, with no outstanding debt.
Share Repurchase Repurchased over 800,000 shares for about $12 million.
Home Care Staffing Growth: Home care staffing has continued its steady growth, up 13% year-over-year in the third quarter.
Physician Staffing Growth: Physician staffing has continued to grow up 4% sequentially and 10% year-over-year.
Education Business Growth: Education business is performing well, approaching $100 million on an annualized run base.
Travel Nurse and Allied Market: Orders are up roughly 20% over the third quarter, indicating a potential inflection point.
MSP Wins: Recent MSP wins are expected to contribute positively to the business.
Cost Management: Proactive cost management has improved contribution income by 15% sequentially and 80% year-over-year.
Headcount Reduction: Investment in headcount reduced by another 4%, driving approximately $2 million per quarter in savings.
Technology Investment: Continued investment in technology, notably on client and candidate facing tools as well as ERP system.
Share Repurchase: Repurchased 800,000 shares for about $12 million in the third quarter.
Competitive Pressures: The company is operating in a highly competitive market, particularly in Travel, Nurse, and Allied sectors, where competitors are offering high compensation packages, pressuring bill pay spreads and limiting gross margin normalization.
Regulatory Issues: The company referenced known and unknown risks, uncertainties, and other factors that could materially affect results, as noted in their filings with the SEC.
Supply Chain Challenges: There are challenges related to bill pay spread compression in the travel business, where pay rates are declining faster than bill rates, impacting gross margins.
Economic Factors: The overall economic conditions are affecting the travel staffing market, with a noted decline in professionals on assignment and normalization in bill rates.
Labor Disruption: A small labor disruption impacted the third quarter performance, which is not expected to recur in the fourth quarter.
Cost Management: The company has been proactive in managing costs due to lower revenue and gross margin pressures, including a reduction in headcount.
Home Care Staffing Growth: Home care staffing has continued its steady growth, up 13% year-over-year in Q3 2024. The company expects this business to be up again in the mid-teens year-over-year in Q4 2024.
Physician Staffing Growth: The physician staffing business has grown 4% sequentially and 10% year-over-year. For 2024, it is forecasted to be up in the low double digits year-over-year.
Education Business Growth: The education business is expected to see continued mid to high single-digit growth for the foreseeable future.
Intellify Technology Platform: The company expects 100% of clients to be fully converted to the Intellify platform by the end of the year, which is anticipated to increase spend under management in 2025.
M&A Opportunities: The company is exploring M&A opportunities to expand its portfolio in markets with strong growth potential.
Q4 2024 Revenue Guidance: The company anticipates Q4 2024 revenue to be between $300 million and $310 million.
Q4 2024 Adjusted EBITDA Guidance: Adjusted EBITDA is expected to be between $11 million and $13 million, reflecting gross margin pressures.
2024 Adjusted Earnings Per Share Guidance: Adjusted earnings per share is expected to be between $0.10 and $0.14.
Long-term Margin Goals: The company aims for a high single-digit adjusted EBITDA margin, with expectations for mid-single digits in the near term.
Share Repurchase: In the third quarter, the company repurchased more than 800,000 shares at an aggregate cost of $12 million.
The earnings call reveals several challenges: revenue and gross profit declines, competitive pressures, and margin compression. Despite share repurchases, the financial performance is weak with declining revenue and pressured margins. The Q&A highlights concerns about margin pressures and unclear future guidance, indicating potential uncertainties. The market strategy and financial health ratings are negatively impacted by these factors, leading to an overall negative sentiment.
The earnings call presents a mixed picture: strong cash flow, share repurchases, and positive guidance on demand increase are offset by significant revenue decline, competitive pressures, and a substantial bad debt expense. The Q&A reveals optimism about demand but acknowledges competitive challenges and cost pressures. The neutral rating reflects these balanced positives and negatives, with no strong catalyst for significant stock price movement.
The earnings call highlights several negative trends, including declining revenue in the Nurse and Allied business, increasing DSO, and gross margin underperformance. Despite some optimism about the Locum business and technology investments, the lack of clear guidance and significant challenges in key segments overshadow positive aspects. Q&A further emphasizes demand softness and management's vague responses, leading to a negative sentiment. With no market cap data, the reaction could vary, but the overall sentiment leans negative due to the revenue decline and uncertainties.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.